Global Human Growth Hormone Market By Route of Administration (Subcutaneous, Intramuscular, Intravenous); By Type (Pediatric Growth Hormone Deficiency (GHD), Prader-Willi Syndrome, Turner Syndrome, Idiopathic Short Stature, Small for Gestational Age, Adult Growth Hormone Deficiency (GHD) (Non-Weight Based, Weight Based)); By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
The rise in prevalence of hormone deficiency disorders in worldwide populations is driving the demand for human growth hormone.
Human growth hormones is a peptide hormone that is synthesized and secreted by cells called somatotrophs in the anterior pituitary gland. These growth hormones play a vital role in the modulation of growth from birth until completion of puberty. They are essential in cell proliferation, bone formation, muscle strength, organogenesis and somatic growth because they stimulate the rate of protein synthesis and the mobilization and utilization of fatty acids. Human growth hormones are also important in the control of body anabolism throughout life. Deficiency of these hormones is a disorder characterized by the inadequate secretion of growth hormone which decrease the linear growth of humans to half or one third of the normal rate. This disorder can be present from birth due to genetic mutations or from structural defects in the brain. It can also be acquired in later stages of life as a result of trauma, infection, radiation therapy or tumor growth within the brain. Prevalence of the growth hormone deficiency is increasing across various regions. Public health studies conducted by different researchers show that in the U.S., 2 out of every 100,000 people have growth hormone deficiency whereas in the U.K, 1 in every 3500 people have this disorder. The medical treatment of these people encompasses external administration of synthetically produced growth hormones which are termed as recombinant human growth hormone. These hormones are manufactured to be nearly identical to the main form of the naturally occurring human growth hormone for stimulating tissue growth, linear growth and metabolism of protein, carbohydrate, lipid, and minerals. Thus, the growing prevalence of growth hormone deficiencies is driving the demand in human growth hormones market across the globe.
Despite of the multiple benefits offered by human growth hormones in treatment of various disorders, concerns related to the side effects of these drugs is restraining their adoption. These drugs are used as an anti-aging treatment in older adults and as a performance-enhancing drug by bodybuilders which sometimes leads to overdose for obtaining results faster. This overdose of growth hormone drugs causes fluid retention and discomfort in the joints. It also causes increase in blood sugar levels among few people. These side-effects leads to discontinuation of the growth hormone consumption, thus, hindering the growth of global human growth hormones market.
Efficacy of growth hormone therapy is dependent on patients' adherence to their treatment regimen. The current therapies are based on administration of growth hormones on daily basis which creates reluctance in patients and poses need for reducing the frequency of administration of growth hormone drugs. Hence, many patients who currently fail to take their daily human growth hormone drugs are opting for long-acting drugs administered either once per week or once every two weeks. Market players have recognized this trend and are introducing growth hormone drugs for consumption on weekly intervals. For instance, Novo Nordisk Health Care AG gained approval from the U.S Food and Drug Administration for its Sogroya growth hormone product in August 2020. This product is long-acting growth hormone growth drug which can be administered once in a week thus, it reduces the injection-site related adverse events such as lipohypertrophy and pruritus. Hence, the development of drugs with reduced administration frequency are anticipated to propel the growth of global human growth hormones market in forecast years.
The recent outbreak of COVID-19 pandemic has infected more than 36.79 million people across several countries and caused death of 1.06 million people. These healthcare crisis have fuelled research activities around the world to develop and effective vaccine or treatment or drug for COVID-19. Scientists are working on developing a human growth hormone based drug for preventing the spread of coronavirus in an active patient’s body. This virus infects the epithelial cells in the lungs which have a life span of 7 days. As these epithelial cells in lung will die and get reborn at different times, in 14 days all the epithelial cells in lungs will be replaced by new ones. In this period the coronavirus has to develop and spread to other cells and organs. This incubation period of 14 days can be reduced by introducing a growth hormone which accelerates the reproduction of cells and reduces the chances of spreading of infection. Researchers have also found that growth hormone therapy for obese COVID-19 patients leads to faster recovery. Thus, the on-going research activities to use growth hormones for treatment of COVID-19 patients is anticipated to fuel the growth of global human growth hormones market.
Route of Administration Outlook:
Based on the route of administration, subcutaneous route is the most preferred route as it gives identical results to intravenous and intramuscular routes, causes less pain and has low incidence of growth hormone antibody development. Market players are introducing new subcutaneous drug delivery systems which eliminates the presence of needle and reduces the pain associated with the growth hormone therapy. For instance, Ferring Pharmaceuticals launched ZOMA-Jet 10 a needle-free human growth hormone delivery system in September 2018. Other companies such as Sandoz Inc. (Novartis AG) and Teva Pharmaceutical Industries Ltd also provide needle-free systems for subcutaneous delivery of growth hormones. Thus, the benefits and advancements in subcutaneous route of administration are driving its share in global human growth hormones market.
Regional Outlook:
North America region registered the highest share in global human growth hormone market in 2018 owing to extensive range of product offerings and on-going research and development activities for developing new drugs. Many pharmaceutical companies in the region are developing novel human growth hormone drugs for treatment of various disorders. For instance, Ascendis Pharma A/S is currently developing a range of human growth hormone drugs including TransCon hGH, TransCon PTH and TransCon CNP which are long-acting drugs for treatment of growth hormone deficiency, hypoparathyroidism and achondroplasia respectively. These ongoing investments towards development of novel products to cater the patients with endocrine disorders are propelling the share of North America region in global human growth hormone market.
In terms of revenue, global human growth hormone market was valued at US$ 4109.23 million in 2019 and is expected to reach US$ 5819.32 million by 2028, growing at an estimated growth rate of 8.9% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Human Growth Hormone Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of human growth hormone market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the human growth hormone market are AnkeBio Co., Ltd, Ascendis Pharma A/S, BTG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ferring Pharmaceuticals, Ipsen Pharma, LifeTein, LLC., Merck Serono, Novo Nordisk Health Care AG, Pfizer Inc., Sandoz Inc. (Novartis AG), Teva Pharmaceutical Industries Ltd, Theratechnologies Inc., Versartis, Inc. and Vetter Pharma-Fertigung GmbH & Co. KG amongst others.
Global Human Growth Hormone Market:
By Route of Administration
- Subcutaneous
- Intramuscular
- Intravenous
By Type
- Pediatric Growth Hormone Deficiency (GHD)
- Prader-Willi Syndrome
- Turner Syndrome
- Idiopathic Short Stature
- Small for Gestational Age
- Adult Growth Hormone Deficiency (GHD)
- Non-Weight Based
- Weight Based
By Distribution Channel
- Hospitals
- Clinics
- Retail Pharmacies
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Human Growth Hormone Market
6. Market
Synopsis: Human Growth Hormone Market
7. Human
Growth Hormone Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Human Growth Hormone Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Human Growth Hormone Market
7.6. Porter’s
Five Force Analysis
8. Global
Human Growth Hormone Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Human Growth Hormone Market Revenue (US$ Mn)
8.2. Global
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
8.2.1. Subcutaneous
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Intramuscular
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Intravenous
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By Route
of Administration
9. Global
Human Growth Hormone Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
9.2.1. Pediatric
Growth Hormone Deficiency (GHD)
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Prader-Willi
Syndrome
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Turner
Syndrome
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Idiopathic
Short Stature
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.2.5. Small
for Gestational Age
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2013 – 2018
9.2.5.3. Market
Forecast, 2019 – 2027
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2013 – 2018
9.2.5.5.1.2. Market
Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2018
9.2.5.5.2.2. Market
Forecast, 2019 – 2027
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2018
9.2.5.5.3.2. Market
Forecast, 2019 – 2027
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2018
9.2.5.5.4.2. Market
Forecast, 2019 – 2027
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2013 – 2018
9.2.5.5.5.2. Market
Forecast, 2019 – 2027
9.2.6. Adult
Growth Hormone Deficiency (GHD) (Definition, Market Estimation and Penetration,
2013 – 2018, Market Estimation (2013 – 2018), Market Forecast (2019 – 2027),
Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America,
Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on
Non-Weight Based, Weight Based)
9.2.6.1. Non-Weight
Based
9.2.6.2. Weight
Based
9.3. Key
Segment for Channeling Investments
9.3.1. By Type
10. Global
Human Growth Hormone Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Clinics
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Retail
Pharmacies
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2013 – 2018
10.2.4.3. Market
Forecast, 2019 – 2027
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2013 – 2018
10.2.4.5.1.2. Market
Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2013 – 2018
10.2.4.5.2.2. Market
Forecast, 2019 – 2027
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2013 – 2018
10.2.4.5.3.2. Market
Forecast, 2019 – 2027
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2013 – 2018
10.2.4.5.4.2. Market
Forecast, 2019 – 2027
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2013 – 2018
10.2.4.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By Distribution
Channel
11. North
America Human Growth Hormone Market Analysis and Forecasts, 2019 - 2027
11.1. Overview
11.1.1. North
America Human Growth Hormone Market Revenue (US$ Mn)
11.2. North
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
11.2.1. Subcutaneous
11.2.2. Intramuscular
11.2.3. Intravenous
11.3. North
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
11.3.1. Pediatric
Growth Hormone Deficiency (GHD)
11.3.2. Prader-Willi
Syndrome
11.3.3. Turner
Syndrome
11.3.4. Idiopathic
Short Stature
11.3.5. Small
for Gestational Age
11.3.6. Adult
Growth Hormone Deficiency (GHD)
11.3.6.1. Non-Weight
Based
11.3.6.2. Weight
Based
11.4. North
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Retail
Pharmacies
11.4.4. Others
11.5. North
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
11.5.1.1.1. Subcutaneous
11.5.1.1.2. Intramuscular
11.5.1.1.3. Intravenous
11.5.1.2. U.S
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
11.5.1.2.1. Pediatric
Growth Hormone Deficiency (GHD)
11.5.1.2.2. Prader-Willi
Syndrome
11.5.1.2.3. Turner
Syndrome
11.5.1.2.4. Idiopathic
Short Stature
11.5.1.2.5. Small
for Gestational Age
11.5.1.2.6. Adult
Growth Hormone Deficiency (GHD)
11.5.1.2.6.1. Non-Weight
Based
11.5.1.2.6.2. Weight
Based
11.5.1.3. U.S
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.5.1.3.1. Hospitals
11.5.1.3.2. Clinics
11.5.1.3.3. Retail
Pharmacies
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
11.5.2.1.1. Subcutaneous
11.5.2.1.2. Intramuscular
11.5.2.1.3. Intravenous
11.5.2.2. Canada
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
11.5.2.2.1. Pediatric
Growth Hormone Deficiency (GHD)
11.5.2.2.2. Prader-Willi
Syndrome
11.5.2.2.3. Turner
Syndrome
11.5.2.2.4. Idiopathic
Short Stature
11.5.2.2.5. Small
for Gestational Age
11.5.2.2.6. Adult
Growth Hormone Deficiency (GHD)
11.5.2.2.6.1. Non-Weight
Based
11.5.2.2.6.2. Weight
Based
11.5.2.3. Canada
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.5.2.3.1. Hospitals
11.5.2.3.2. Clinics
11.5.2.3.3. Retail
Pharmacies
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
11.5.3.1.1. Subcutaneous
11.5.3.1.2. Intramuscular
11.5.3.1.3. Intravenous
11.5.3.2. Mexico
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
11.5.3.2.1. Pediatric
Growth Hormone Deficiency (GHD)
11.5.3.2.2. Prader-Willi
Syndrome
11.5.3.2.3. Turner
Syndrome
11.5.3.2.4. Idiopathic
Short Stature
11.5.3.2.5. Small
for Gestational Age
11.5.3.2.6. Adult
Growth Hormone Deficiency (GHD)
11.5.3.2.6.1. Non-Weight
Based
11.5.3.2.6.2. Weight
Based
11.5.3.3. Mexico
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.5.3.3.1. Hospitals
11.5.3.3.2. Clinics
11.5.3.3.3. Retail
Pharmacies
11.5.3.3.4. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
11.5.4.1.1. Subcutaneous
11.5.4.1.2. Intramuscular
11.5.4.1.3. Intravenous
11.5.4.2. Rest
of North America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.4.2.1. Pediatric
Growth Hormone Deficiency (GHD)
11.5.4.2.2. Prader-Willi
Syndrome
11.5.4.2.3. Turner
Syndrome
11.5.4.2.4. Idiopathic
Short Stature
11.5.4.2.5. Small
for Gestational Age
11.5.4.2.6. Adult
Growth Hormone Deficiency (GHD)
11.5.4.2.6.1. Non-Weight
Based
11.5.4.2.6.2. Weight
Based
11.5.4.3. Rest
of North America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.5.4.3.1. Hospitals
11.5.4.3.2. Clinics
11.5.4.3.3. Retail
Pharmacies
11.5.4.3.4. Others
11.6. Key Segment
for Channeling Investments
11.6.1. By
Country
11.6.2. By
Route of Administration
11.6.3. By Type
11.6.4. By
Distribution Channel
12. Europe
Human Growth Hormone Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Europe
Human Growth Hormone Market Revenue (US$ Mn)
12.2. Europe
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.2.1. Subcutaneous
12.2.2. Intramuscular
12.2.3. Intravenous
12.3. Europe
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.3.1. Pediatric
Growth Hormone Deficiency (GHD)
12.3.2. Prader-Willi
Syndrome
12.3.3. Turner
Syndrome
12.3.4. Idiopathic
Short Stature
12.3.5. Small
for Gestational Age
12.3.6. Adult
Growth Hormone Deficiency (GHD)
12.3.6.1. Non-Weight
Based
12.3.6.2. Weight
Based
12.4. Europe
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Retail Pharmacies
12.4.4. Others
12.5. Europe
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.5.1.1.1. Subcutaneous
12.5.1.1.2. Intramuscular
12.5.1.1.3. Intravenous
12.5.1.2. France
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.1.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.1.2.2. Prader-Willi
Syndrome
12.5.1.2.3. Turner
Syndrome
12.5.1.2.4. Idiopathic
Short Stature
12.5.1.2.5. Small
for Gestational Age
12.5.1.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.1.2.6.1. Non-Weight
Based
12.5.1.2.6.2. Weight
Based
12.5.1.3. France
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.1.3.1. Hospitals
12.5.1.3.2. Clinics
12.5.1.3.3. Retail
Pharmacies
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The
UK Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.5.2.1.1. Subcutaneous
12.5.2.1.2. Intramuscular
12.5.2.1.3. Intravenous
12.5.2.2. The
UK Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.2.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.2.2.2. Prader-Willi
Syndrome
12.5.2.2.3. Turner
Syndrome
12.5.2.2.4. Idiopathic
Short Stature
12.5.2.2.5. Small
for Gestational Age
12.5.2.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.2.2.6.1. Non-Weight
Based
12.5.2.2.6.2. Weight
Based
12.5.2.3. The
UK Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.2.3.1. Hospitals
12.5.2.3.2. Clinics
12.5.2.3.3. Retail
Pharmacies
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.5.3.1.1. Subcutaneous
12.5.3.1.2. Intramuscular
12.5.3.1.3. Intravenous
12.5.3.2. Spain
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.3.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.3.2.2. Prader-Willi
Syndrome
12.5.3.2.3. Turner
Syndrome
12.5.3.2.4. Idiopathic
Short Stature
12.5.3.2.5. Small
for Gestational Age
12.5.3.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.3.2.6.1. Non-Weight
Based
12.5.3.2.6.2. Weight
Based
12.5.3.3. Spain
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.3.3.1. Hospitals
12.5.3.3.2. Clinics
12.5.3.3.3. Retail
Pharmacies
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.5.4.1.1. Subcutaneous
12.5.4.1.2. Intramuscular
12.5.4.1.3. Intravenous
12.5.4.2. Germany
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.4.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.4.2.2. Prader-Willi
Syndrome
12.5.4.2.3. Turner
Syndrome
12.5.4.2.4. Idiopathic
Short Stature
12.5.4.2.5. Small
for Gestational Age
12.5.4.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.4.2.6.1. Non-Weight
Based
12.5.4.2.6.2. Weight
Based
12.5.4.3. Germany
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.4.3.1. Hospitals
12.5.4.3.2. Clinics
12.5.4.3.3. Retail
Pharmacies
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.5.5.1.1. Subcutaneous
12.5.5.1.2. Intramuscular
12.5.5.1.3. Intravenous
12.5.5.2. Italy
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.5.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.5.2.2. Prader-Willi
Syndrome
12.5.5.2.3. Turner
Syndrome
12.5.5.2.4. Idiopathic
Short Stature
12.5.5.2.5. Small
for Gestational Age
12.5.5.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.5.2.6.1. Non-Weight
Based
12.5.5.2.6.2. Weight
Based
12.5.5.3. Italy
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.5.3.1. Hospitals
12.5.5.3.2. Clinics
12.5.5.3.3. Retail
Pharmacies
12.5.5.3.4. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.5.6.1.1. Subcutaneous
12.5.6.1.2. Intramuscular
12.5.6.1.3. Intravenous
12.5.6.2. Nordic
Countries Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.6.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.6.2.2. Prader-Willi
Syndrome
12.5.6.2.3. Turner
Syndrome
12.5.6.2.4. Idiopathic
Short Stature
12.5.6.2.5. Small
for Gestational Age
12.5.6.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.6.2.6.1. Non-Weight
Based
12.5.6.2.6.2. Weight
Based
12.5.6.3. Nordic
Countries Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.5.6.3.1. Hospitals
12.5.6.3.2. Clinics
12.5.6.3.3. Retail
Pharmacies
12.5.6.3.4. Others
12.5.6.4. Nordic
Countries Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.5.7.1.1. Subcutaneous
12.5.7.1.2. Intramuscular
12.5.7.1.3. Intravenous
12.5.7.2. Benelux
Union Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.7.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.7.2.2. Prader-Willi
Syndrome
12.5.7.2.3. Turner
Syndrome
12.5.7.2.4. Idiopathic
Short Stature
12.5.7.2.5. Small
for Gestational Age
12.5.7.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.7.2.6.1. Non-Weight
Based
12.5.7.2.6.2. Weight
Based
12.5.7.3. Benelux
Union Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.5.7.3.1. Hospitals
12.5.7.3.2. Clinics
12.5.7.3.3. Retail
Pharmacies
12.5.7.3.4. Others
12.5.7.4. Benelux
Union Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.5.8.1.1. Subcutaneous
12.5.8.1.2. Intramuscular
12.5.8.1.3. Intravenous
12.5.8.2. Rest
of Europe Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
12.5.8.2.1. Pediatric
Growth Hormone Deficiency (GHD)
12.5.8.2.2. Prader-Willi
Syndrome
12.5.8.2.3. Turner
Syndrome
12.5.8.2.4. Idiopathic
Short Stature
12.5.8.2.5. Small
for Gestational Age
12.5.8.2.6. Adult
Growth Hormone Deficiency (GHD)
12.5.8.2.6.1. Non-Weight
Based
12.5.8.2.6.2. Weight
Based
12.5.8.3. Rest
of Europe Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.5.8.3.1. Hospitals
12.5.8.3.2. Clinics
12.5.8.3.3. Retail
Pharmacies
12.5.8.3.4. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Route of Administration
12.6.3. By Type
12.6.4. By
Distribution Channel
13. Asia
Pacific Human Growth Hormone Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Asia
Pacific Human Growth Hormone Market Revenue (US$ Mn)
13.2. Asia
Pacific Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.2.1. Subcutaneous
13.2.2. Intramuscular
13.2.3. Intravenous
13.3. Asia
Pacific Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.3.1. Pediatric
Growth Hormone Deficiency (GHD)
13.3.2. Prader-Willi
Syndrome
13.3.3. Turner
Syndrome
13.3.4. Idiopathic
Short Stature
13.3.5. Small
for Gestational Age
13.3.6. Adult
Growth Hormone Deficiency (GHD)
13.3.6.1. Non-Weight
Based
13.3.6.2. Weight
Based
13.4. Asia
Pacific Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Retail
Pharmacies
13.4.4. Others
13.5. Asia
Pacific Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.5.1.1.1. Subcutaneous
13.5.1.1.2. Intramuscular
13.5.1.1.3. Intravenous
13.5.1.2. China
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.5.1.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.1.2.2. Prader-Willi
Syndrome
13.5.1.2.3. Turner
Syndrome
13.5.1.2.4. Idiopathic
Short Stature
13.5.1.2.5. Small
for Gestational Age
13.5.1.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.1.2.6.1. Non-Weight
Based
13.5.1.2.6.2. Weight
Based
13.5.1.3. China
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.1.3.1. Hospitals
13.5.1.3.2. Clinics
13.5.1.3.3. Retail
Pharmacies
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.5.2.1.1. Subcutaneous
13.5.2.1.2. Intramuscular
13.5.2.1.3. Intravenous
13.5.2.2. Japan
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.5.2.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.2.2.2. Prader-Willi
Syndrome
13.5.2.2.3. Turner
Syndrome
13.5.2.2.4. Idiopathic
Short Stature
13.5.2.2.5. Small
for Gestational Age
13.5.2.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.2.2.6.1. Non-Weight
Based
13.5.2.2.6.2. Weight
Based
13.5.2.3. Japan
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.2.3.1. Hospitals
13.5.2.3.2. Clinics
13.5.2.3.3. Retail
Pharmacies
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.5.3.1.1. Subcutaneous
13.5.3.1.2. Intramuscular
13.5.3.1.3. Intravenous
13.5.3.2. India
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.5.3.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.3.2.2. Prader-Willi
Syndrome
13.5.3.2.3. Turner
Syndrome
13.5.3.2.4. Idiopathic
Short Stature
13.5.3.2.5. Small
for Gestational Age
13.5.3.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.3.2.6.1. Non-Weight
Based
13.5.3.2.6.2. Weight
Based
13.5.3.3. India
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.3.3.1. Hospitals
13.5.3.3.2. Clinics
13.5.3.3.3. Retail
Pharmacies
13.5.3.3.4. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.5.4.1.1. Subcutaneous
13.5.4.1.2. Intramuscular
13.5.4.1.3. Intravenous
13.5.4.2. New
Zealand Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.5.4.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.4.2.2. Prader-Willi
Syndrome
13.5.4.2.3. Turner
Syndrome
13.5.4.2.4. Idiopathic
Short Stature
13.5.4.2.5. Small
for Gestational Age
13.5.4.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.4.2.6.1. Non-Weight
Based
13.5.4.2.6.2. Weight
Based
13.5.4.3. New
Zealand Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.4.3.1. Hospitals
13.5.4.3.2. Clinics
13.5.4.3.3. Retail
Pharmacies
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.5.5.1.1. Subcutaneous
13.5.5.1.2. Intramuscular
13.5.5.1.3. Intravenous
13.5.5.2. Australia
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.5.5.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.5.2.2. Prader-Willi
Syndrome
13.5.5.2.3. Turner
Syndrome
13.5.5.2.4. Idiopathic
Short Stature
13.5.5.2.5. Small
for Gestational Age
13.5.5.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.5.2.6.1. Non-Weight
Based
13.5.5.2.6.2. Weight
Based
13.5.5.3. Australia
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.5.3.1. Hospitals
13.5.5.3.2. Clinics
13.5.5.3.3. Retail
Pharmacies
13.5.5.3.4. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.5.6.1.1. Subcutaneous
13.5.6.1.2. Intramuscular
13.5.6.1.3. Intravenous
13.5.6.2. South
Korea Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.5.6.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.6.2.2. Prader-Willi
Syndrome
13.5.6.2.3. Turner
Syndrome
13.5.6.2.4. Idiopathic
Short Stature
13.5.6.2.5. Small
for Gestational Age
13.5.6.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.6.2.6.1. Non-Weight
Based
13.5.6.2.6.2. Weight
Based
13.5.6.3. South
Korea Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.6.3.1. Hospitals
13.5.6.3.2. Clinics
13.5.6.3.3. Retail
Pharmacies
13.5.6.3.4. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.5.7.1.1. Subcutaneous
13.5.7.1.2. Intramuscular
13.5.7.1.3. Intravenous
13.5.7.2. Southeast
Asia Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
13.5.7.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.7.2.2. Prader-Willi
Syndrome
13.5.7.2.3. Turner
Syndrome
13.5.7.2.4. Idiopathic
Short Stature
13.5.7.2.5. Small
for Gestational Age
13.5.7.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.7.2.6.1. Non-Weight
Based
13.5.7.2.6.2. Weight
Based
13.5.7.3. Southeast
Asia Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.7.3.1. Hospitals
13.5.7.3.2. Clinics
13.5.7.3.3. Retail
Pharmacies
13.5.7.3.4. Others
13.5.7.4. Southeast
Asia Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.5.8.1.1. Subcutaneous
13.5.8.1.2. Intramuscular
13.5.8.1.3. Intravenous
13.5.8.2. Rest
of Asia Pacific Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.8.2.1. Pediatric
Growth Hormone Deficiency (GHD)
13.5.8.2.2. Prader-Willi
Syndrome
13.5.8.2.3. Turner
Syndrome
13.5.8.2.4. Idiopathic
Short Stature
13.5.8.2.5. Small
for Gestational Age
13.5.8.2.6. Adult
Growth Hormone Deficiency (GHD)
13.5.8.2.6.1. Non-Weight
Based
13.5.8.2.6.2. Weight
Based
13.5.8.3. Rest
of Asia Pacific Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.8.3.1. Hospitals
13.5.8.3.2. Clinics
13.5.8.3.3. Retail
Pharmacies
13.5.8.3.4. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Route of Administration
13.6.3. By Type
13.6.4. By
Distribution Channel
14. Middle
East and Africa Human Growth Hormone Market Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Middle
East and Africa Human Growth Hormone Market Revenue (US$ Mn)
14.2. Middle
East and Africa Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.2.1. Subcutaneous
14.2.2. Intramuscular
14.2.3. Intravenous
14.3. Middle
East and Africa Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Type
14.3.1. Pediatric
Growth Hormone Deficiency (GHD)
14.3.2. Prader-Willi
Syndrome
14.3.3. Turner Syndrome
14.3.4. Idiopathic
Short Stature
14.3.5. Small
for Gestational Age
14.3.6. Adult
Growth Hormone Deficiency (GHD)
14.3.6.1. Non-Weight
Based
14.3.6.2. Weight
Based
14.4. Middle
East and Africa Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Retail
Pharmacies
14.4.4. Others
14.5. Middle
East and Africa Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.5.1.1.1. Subcutaneous
14.5.1.1.2. Intramuscular
14.5.1.1.3. Intravenous
14.5.1.2. Saudi
Arabia Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
14.5.1.2.1. Pediatric
Growth Hormone Deficiency (GHD)
14.5.1.2.2. Prader-Willi
Syndrome
14.5.1.2.3. Turner
Syndrome
14.5.1.2.4. Idiopathic
Short Stature
14.5.1.2.5. Small
for Gestational Age
14.5.1.2.6. Adult
Growth Hormone Deficiency (GHD)
14.5.1.2.6.1. Non-Weight
Based
14.5.1.2.6.2. Weight
Based
14.5.1.3. Saudi
Arabia Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.1.3.1. Hospitals
14.5.1.3.2. Clinics
14.5.1.3.3. Retail
Pharmacies
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.5.2.1.1. Subcutaneous
14.5.2.1.2. Intramuscular
14.5.2.1.3. Intravenous
14.5.2.2. UAE
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
14.5.2.2.1. Pediatric
Growth Hormone Deficiency (GHD)
14.5.2.2.2. Prader-Willi
Syndrome
14.5.2.2.3. Turner
Syndrome
14.5.2.2.4. Idiopathic
Short Stature
14.5.2.2.5. Small
for Gestational Age
14.5.2.2.6. Adult
Growth Hormone Deficiency (GHD)
14.5.2.2.6.1. Non-Weight
Based
14.5.2.2.6.2. Weight
Based
14.5.2.3. UAE
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.2.3.1. Hospitals
14.5.2.3.2. Clinics
14.5.2.3.3. Retail
Pharmacies
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.5.3.1.1. Subcutaneous
14.5.3.1.2. Intramuscular
14.5.3.1.3. Intravenous
14.5.3.2. Egypt
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
14.5.3.2.1. Pediatric
Growth Hormone Deficiency (GHD)
14.5.3.2.2. Prader-Willi
Syndrome
14.5.3.2.3. Turner
Syndrome
14.5.3.2.4. Idiopathic
Short Stature
14.5.3.2.5. Small
for Gestational Age
14.5.3.2.6. Adult
Growth Hormone Deficiency (GHD)
14.5.3.2.6.1. Non-Weight
Based
14.5.3.2.6.2. Weight
Based
14.5.3.3. Egypt
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.3.3.1. Hospitals
14.5.3.3.2. Clinics
14.5.3.3.3. Retail
Pharmacies
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.5.4.1.1. Subcutaneous
14.5.4.1.2. Intramuscular
14.5.4.1.3. Intravenous
14.5.4.2. Kuwait
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
14.5.4.2.1. Pediatric
Growth Hormone Deficiency (GHD)
14.5.4.2.2. Prader-Willi
Syndrome
14.5.4.2.3. Turner
Syndrome
14.5.4.2.4. Idiopathic
Short Stature
14.5.4.2.5. Small
for Gestational Age
14.5.4.2.6. Adult
Growth Hormone Deficiency (GHD)
14.5.4.2.6.1. Non-Weight
Based
14.5.4.2.6.2. Weight
Based
14.5.4.3. Kuwait
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.4.3.1. Hospitals
14.5.4.3.2. Clinics
14.5.4.3.3. Retail
Pharmacies
14.5.4.3.4. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.5.5.1.1. Subcutaneous
14.5.5.1.2. Intramuscular
14.5.5.1.3. Intravenous
14.5.5.2. South
Africa Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
14.5.5.2.1. Pediatric
Growth Hormone Deficiency (GHD)
14.5.5.2.2. Prader-Willi
Syndrome
14.5.5.2.3. Turner
Syndrome
14.5.5.2.4. Idiopathic
Short Stature
14.5.5.2.5. Small
for Gestational Age
14.5.5.2.6. Adult
Growth Hormone Deficiency (GHD)
14.5.5.2.6.1. Non-Weight
Based
14.5.5.2.6.2. Weight
Based
14.5.5.3. South
Africa Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.5.3.1. Hospitals
14.5.5.3.2. Clinics
14.5.5.3.3. Retail
Pharmacies
14.5.5.3.4. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Human Growth Hormone Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.5.6.1.1. Subcutaneous
14.5.6.1.2. Intramuscular
14.5.6.1.3. Intravenous
14.5.6.2. Rest
of Middle East & Africa Human Growth Hormone Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.6.2.1. Pediatric
Growth Hormone Deficiency (GHD)
14.5.6.2.2. Prader-Willi
Syndrome
14.5.6.2.3. Turner
Syndrome
14.5.6.2.4. Idiopathic
Short Stature
14.5.6.2.5. Small
for Gestational Age
14.5.6.2.6. Adult
Growth Hormone Deficiency (GHD)
14.5.6.2.6.1. Non-Weight
Based
14.5.6.2.6.2. Weight
Based
14.5.6.3. Rest
of Middle East & Africa Human Growth Hormone Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.6.3.1. Hospitals
14.5.6.3.2. Clinics
14.5.6.3.3. Retail
Pharmacies
14.5.6.3.4. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By Country
14.6.2. By
Route of Administration
14.6.3. By Type
14.6.4. By
Distribution Channel
15. Latin
America Human Growth Hormone Market Analysis and Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Latin
America Human Growth Hormone Market Revenue (US$ Mn)
15.2. Latin
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.2.1. Subcutaneous
15.2.2. Intramuscular
15.2.3. Intravenous
15.3. Latin
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
15.3.1. Pediatric
Growth Hormone Deficiency (GHD)
15.3.2. Prader-Willi
Syndrome
15.3.3. Turner
Syndrome
15.3.4. Idiopathic
Short Stature
15.3.5. Small
for Gestational Age
15.3.6. Adult
Growth Hormone Deficiency (GHD)
15.3.6.1. Non-Weight
Based
15.3.6.2. Weight
Based
15.4. Latin
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.4.1. Hospitals
15.4.2. Clinics
15.4.3. Retail
Pharmacies
15.4.4. Others
15.5. Latin
America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.5.1.1.1. Subcutaneous
15.5.1.1.2. Intramuscular
15.5.1.1.3. Intravenous
15.5.1.2. Brazil
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
15.5.1.2.1. Pediatric
Growth Hormone Deficiency (GHD)
15.5.1.2.2. Prader-Willi
Syndrome
15.5.1.2.3. Turner
Syndrome
15.5.1.2.4. Idiopathic
Short Stature
15.5.1.2.5. Small
for Gestational Age
15.5.1.2.6. Adult
Growth Hormone Deficiency (GHD)
15.5.1.2.6.1. Non-Weight
Based
15.5.1.2.6.2. Weight
Based
15.5.1.3. Brazil
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.5.1.3.1. Hospitals
15.5.1.3.2. Clinics
15.5.1.3.3. Retail
Pharmacies
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.5.2.1.1. Subcutaneous
15.5.2.1.2. Intramuscular
15.5.2.1.3. Intravenous
15.5.2.2. Argentina
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Type
15.5.2.2.1. Pediatric
Growth Hormone Deficiency (GHD)
15.5.2.2.2. Prader-Willi
Syndrome
15.5.2.2.3. Turner
Syndrome
15.5.2.2.4. Idiopathic
Short Stature
15.5.2.2.5. Small
for Gestational Age
15.5.2.2.6. Adult
Growth Hormone Deficiency (GHD)
15.5.2.2.6.1. Non-Weight
Based
15.5.2.2.6.2. Weight
Based
15.5.2.3. Argentina
Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.5.2.3.1. Hospitals
15.5.2.3.2. Clinics
15.5.2.3.3. Retail
Pharmacies
15.5.2.3.4. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.5.3.1.1. Subcutaneous
15.5.3.1.2. Intramuscular
15.5.3.1.3. Intravenous
15.5.3.2. Rest
of Latin America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Type
15.5.3.2.1. Pediatric
Growth Hormone Deficiency (GHD)
15.5.3.2.2. Prader-Willi
Syndrome
15.5.3.2.3. Turner
Syndrome
15.5.3.2.4. Idiopathic
Short Stature
15.5.3.2.5. Small
for Gestational Age
15.5.3.2.6. Adult
Growth Hormone Deficiency (GHD)
15.5.3.2.6.1. Non-Weight
Based
15.5.3.2.6.2. Weight
Based
15.5.3.3. Rest
of Latin America Human Growth Hormone Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.5.3.3.1. Hospitals
15.5.3.3.2. Clinics
15.5.3.3.3. Retail
Pharmacies
15.5.3.3.4. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Route of Administration
15.6.3. By Type
15.6.4. By
Distribution Channel
16. Competitive
Benchmarking
16.1. Market
Share Analysis, 2018
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player
Profiles
17.1. BTG
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Eli Lilly
and Company
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. F.
Hoffmann-La Roche Ltd
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Merck
Serono
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Novo
Nordisk Health Care AG
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Vetter
Pharma-Fertigung GmbH & Co. KG
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business Strategies
17.7. Other
Industry Participants
18. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
